2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Pathogenesis, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4396 Real-world (Rw) treatment (Tx) patterns, discontinuation and clinical outcomes with first-line (1L) covalent BTK inhibitors (cBTKis) in Medicare beneficiaries with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Scott F. Huntington, MD, MPH, Rohit Ramanlal Mistry, MPharm, MSc, MBA2, Justin T. Puckett3, Sachin Kamal-Bahl, PhD4, Jennifer Prescott, PhD5, Siyang Leng, MD, MS6, Enrico De Nigris, MSc7, Jalpa Doshi, PhD8
1 Yale University School of Medicine, New Haven, Connecticut, United States
2 MSD (UK) Limited, London, United Kingdom
3 COVIA Health Solutions, Ambler, Pennsylvania, United States
4 COVIA Health Solutions, Ambler, Pennsylvania, United States
5 Merck & Co., Inc., Rahway, New Jersey, United States
6 Merck & Co., Inc., Rahway, New Jersey, United States
7 MSD (UK) Limited, London, United Kingdom
8 University of Pennsylvania, Philadelphia, Pennsylvania, United States

Introduction
cBTKis have transformed CLL/SLL management. While second-generation (2G) cBTKis (acalabrutinib [ACA], zanubrutinib [ZAN]) show improved tolerability over ibrutinib (IBR) in trials, older patients [pts] are underrepresented and thus trial findings may not reflect RW tx patterns and outcomes in routine clinical practice.

Aims
To evaluate tx patterns, time to discontinuation (TTD), adverse events (AEs), and time to next tx or death (TTNT+D) in older Medicare beneficiaries with CLL/SLL on 1L cBTKi therapy.

Methods
This retrospective study of Medicare claims data (2017-2024) identified pts ≥68 years old initiating 1L IBR, ACA, or ZAN. The index date was the first cBTKi prescription. Eligible pts needed continuous Medicare Parts A, B, and D enrolment for ≥36 months [mo] pre-index and ≥12 mo or until death post-index, with ≥1 CLL/SLL diagnosis claim in each period. Pts were stratified by cBTKi and discontinuation status (continuous users, early discontinuers [≤12-mo], late discontinuers [>12-mo]). Outcomes included discontinuation (continuous 60-day gap in index cBTKi tx), TTD, TTNT+D from initiation and discontinuation, AE rates (per 1000 pt-mo; Cardio-Vascular [CV]: Atrial Fibrillation [AF] and Hypertension [HTN]; non-CV: Thrombocytopenia [TCP], Infections, Bleeding, Neutropenia, Headaches) and deaths. Kaplan-Meier (KM) methods estimated TTD and pts receiving Next Tx or Dying (NT+D); Cox regression models identified factors associated with TTD and TTNT+D.

Results
Among 6,192 Medicare beneficiaries (mean age 78.6 ± 6.5 years), 2,574 received IBR and 3,618 received 2G cBTKis (ACA N=2,724 and ZAN N=894). Overall, 63.9% (N=3,954) discontinued tx over a median follow-up of 26.7 mo. Half (N=1,847) of discontinuations occurred within 6 mo and two-thirds (N=2,619) within 12 mo. Of those discontinuing, 41.4% received subsequent tx over a median follow up of 18.6 mo from the date of discontinuation (10.7% restarting index cBTKi, 14.7% another cBTKi, 8.8% a BCL2i regimen, and 7.3% other regimens (0.6% Pirtobrutinib, 4.7% CIT, 2.0% other).

The 24-mo KM rates of discontinuation were: 65.1% (IBR), 58.1% (ACA), and 52.3% (ZAN). Cox regression showed lower discontinuation risk for ACA (HR=0.77, 95% CI 0.72-0.83; p<0.001) and ZAN (HR=0.68, 95% CI 0.59-0.77; p<0.001) vs. IBR.

The 24-mo KM probability of NT+D from index cBTKi initiation was 36.3% for IBR, 26.9% for ACA, and 27.0% for ZAN. From cBTKi discontinuation, the 24-mo probability was 57.2% and 49.7% among early and late discontinuers, respectively. Longer duration of 1L cBTKi therapy was associated with prolonged TTNT+D, with each additional 3 months of treatment associated with a 3% lower risk of NT+D (HR=0.97; 95% CI 0.96-0.99; p<0.001) in the multivariable analysis.

The most prevalent baseline comorbidities were HTN (76%), AF (18%) and TCP (30%). With regards to CV AE incident rates (per 1,000 pt-mo), AF rates were lower with 2G cBTKis (IBR 10.4, ACA 4.9, ZAN 3.9), while HTN rates were similar across cBTKis (IBR: 4.8, ACA: 3.9, ZAN: 5.2). Non-CV AE incident rates were similar across agents (overall, per 1000 pt-mo: TCP: 8.5, Neutropenia: 3.7, bleeding: 23.6, Infection: 31.8, Headaches: 5.7). Compared to continuous users, early discontinuers had substantially higher rates (per 1,000 pt-mo) of CV events (AF: 21.3 vs. 4.4; HTN: 8.3 vs. 3.7) and non-CV events (TCP: 24.9 vs. 5.9; neutropenia: 11.2 vs. 2.5, bleeding: 48.8 vs. 19.5; infection: 73.2 vs. 25.7; headaches: 11.1 vs. 4.5). Late discontinuers also had higher AE rates than continuous users, but lower than early discontinuers.

Of the 1,740 total deaths observed, 32.1% of the events occurred prior to the initiation of second-line therapy.

Conclusions
In this contemporary cohort of older Medicare beneficiaries, early discontinuation of 1L cBTKi was common despite the advent of 2G options, with >50% of patients discontinuing treatment within 24 mo. Among patients who initiated subsequent tx, retreatment with a cBTKi was common. Early discontinuation is associated with higher AE rates, suggesting tolerability may remain a key challenge. Longer 1L cBTKi tx duration is associated with prolonged TTNT+D post-discontinuation, highlighting the importance of optimizing initial tx. These findings underscore the need for durable and safe therapeutic options for older pts with CLL/SLL.

Scott F. Huntington, MD, MPH: AstraZeneca - Honoraria; Genentech - Honoraria; BeOne - Research Funding; Nurix Therapeutics - Research Funding; AbbVie - Research Funding; Merck & Co., Inc. - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Lilly - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)